Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor

Bibliography

• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128(4):683-92
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
   PubMed Web of Science ®Google Scholar
• Seligson DB, Horvath S, Shi T, Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6
   PubMed Web of Science ®Google Scholar
• Tryndyak VP, Kovalchuk O, Pogribny IP. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 2006;5:65-70
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Ross SA, Tryndyak VP, Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 2006;27:1180-6
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51
   PubMed Web of Science ®Google Scholar
• Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007;13:7237-42
   PubMed Web of Science ®Google Scholar
• Buglio D, Georgakis GV, Hanabuchi S, Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424-33
   PubMed Web of Science ®Google Scholar
• Carlisi D, Lauricella M, D'Anneo A, The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009;45:2425-38
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Ausserlechner MJ, Bernhard D, The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98:10833-8
   PubMed Web of Science ®Google Scholar
• Peart MJ, Tainton KM, Ruefli AA, Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63:4460-71
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Fuino L, Stobaugh C, Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003;101:3236-9
   PubMed Web of Science ®Google Scholar
• Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004;101:18030-5
   PubMed Web of Science ®Google Scholar
• Xu WS, Perez G, Ngo L, Induction of polyploidy by histone deacetylase inhibitor:a pathway for antitumor effects. Cancer Res 2005;65:7832-9
   PubMed Web of Science ®Google Scholar
• Hu Y, Lu W, Chen G, Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood 2010;116:2372-741
   Google Scholar
• Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009;280:192-200
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16:1111-20
   PubMed Web of Science ®Google Scholar
• Grant C, Rahman F, Piekarz R, Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 2010;10:997-1008
   PubMed Web of Science ®Google Scholar
• Buglio D, Mamidipudi V, Khaskhely NM, The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 2010;151:387-96
   PubMed Web of Science ®Google Scholar
• El-Khoury V, Moussay E, Janji B, The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 2010;9:1349-60
   PubMed Web of Science ®Google Scholar
• Wei Y, Kadia T, Tong W, The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 2010;16:3923-32
   PubMed Web of Science ®Google Scholar
• Chia K, Beamish H, Jafferi K, Gabrielli B. The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity. Mol Pharmacol 2010;78:436-43
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Siu LL. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. Expert Opin Investig Drugs 2008;17:1247-54
   PubMed Web of Science ®Google Scholar
• Zhou N, Moradei O, Raeppel S, Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 2008;51:4072-5
   PubMed Web of Science ®Google Scholar
• Kelly WK, O'Connor OA, Krug LM, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31
   PubMed Web of Science ®Google Scholar
• Gojo I, Jiemjit A, Trepel JB, Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109:2781-90
   PubMed Web of Science ®Google Scholar
• Ryan QC, Headlee D, Acharya M, Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23:3912-22
   PubMed Web of Science ®Google Scholar
• Bonfils C, Kalita A, Dubay M, Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 2008;14:3441-9
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Assouline S, Cortes J, Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112:981-9
   PubMed Web of Science ®Google Scholar
• Kell J. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. Curr Opin Investig Drugs 2007;8:485-92
   PubMed Web of Science ®Google Scholar
• Siu LL, Pili R, Duran I, Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940-7
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68
   PubMed Web of Science ®Google Scholar
• Lancet JE, Nichols G, Assouline S, A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS) [abstract 2516]. J Clin Oncol 2007;25:101s
   Google Scholar
• Gelmon K, Tolcher A, Carducci M, Phase I trial of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3× weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors. J Clin Oncol 2005;23:3147
   Google Scholar
• Nguyen H, Gravel S, MacLeod AR. Synergistic antitumor activity of the isotype-selective histone deacetylase inhibitor MGCD0103 in combination with gemcitabine [abtsract]. Clin Cancer Res 2005;11(24):9153s
   Web of Science ®Google Scholar
• Hurwitz H, Nelson B, O'Dwyer PJ, The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine in patients with refractory solid tumors. J Clin Oncol 2008;26: abstract 4625
   Google Scholar
• Garcia-Manero G, Yang, AS, Giles F, Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML). Blood 2006;108:1954
   Web of Science ®Google Scholar
• Garcia-Manero G, Yang AS, Klimek V, Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood 2007;110:444
   Web of Science ®Google Scholar
• Younes A, Wedgwood A, McLaughlin P, Treatment of relapsed or refractory lymphomawith the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a Phase II study [abstract]. Blood 2007;110:2571
   Web of Science ®Google Scholar
• Younes A, Pro B, Fanale M, The isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL) [abstract]. Blood 2007;110:2566
   Web of Science ®Google Scholar
• Martell RE, Garcia-Manero G, Younes A, Clinical development of MGCD0103, an isotype-selective HDAC inhibitor: pericarditis/pericardial effusion in the context of overall safety and efficacy [abstract]. Blood 2009;114:4756
   Google Scholar
• Younes A, Bociek RG, Kuruvilla J, Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): update from a Phase II clinical study. Blood 2010;116:1763
   Google Scholar
• Martell RE, Younes A, Assouline SE, Phase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): study reinitiation and update of clinical efficacy and safety. J Clin Oncol 2010;28(Suppl 15s): abstract 8086
   Google Scholar
• Blum KA, Advani A, Fernandez L, Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009;147:507-14
   PubMed Web of Science ®Google Scholar
• Sampat K, Rossi A, Garcia-Gutierrez V, Characteristics of pericardial effusions in patients with leukemia. Cancer 2010;116:2366-71
   PubMed Web of Science ®Google Scholar
• Das DK. Serous effusions in malignant lymphomas: a review. Diagn Cytopathol 2006;34:335-47
   PubMed Web of Science ®Google Scholar
• Liu HB, Mayes PA, Perlmutter P, The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine. Int J Oncol 2011;38:1421-5
   PubMed Web of Science ®Google Scholar